Boston, Massachusetts, United States · Hybrid
$193k–$298k/yr
Company Overview Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that star…
Skills: Alliance Management, Strategic Leadership, Governance, Contract Management, Financial Forecasting
Boston, Massachusetts, United States · Hybrid
$274k–$412k/yr
Company Overview Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that star…
Skills: Clinical Development Strategy, Oncology Drug Development, Study Protocol Design, Medical Monitoring, Regulatory Submissions
Boston, Massachusetts, United States · Hybrid
$145k–$217k/yr
Company Overview Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that star…
Skills: Clinical Data Management, eCOA, Centralized Imaging, IRT, EDC
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
Lead and optimize strategic collaborations with pharmaceutical, biotech, and academic partners to ensure alignment of objectives and execution of contractual obligations. Manage joint governance committees and coordinate cross-functionally to maximize partnership value and mitigate risks.
Requires an advanced degree (PhD/MBA) with 6-8 years of experience, or a Bachelor's degree with 10+ years of alliance management experience in the biotech or pharma industry. Preferred expertise in oncology, rare diseases, and global collaboration management.
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.
The Associate Director/Director, Alliance Management is responsible for leading and optimizing strategic collaborations with pharmaceutical, biotechnology, academic, and technology partners. This role serves as the primary relationship manager for one or more high-value alliances, ensuring alignment of strategic objectives, effective governance, operational excellence, and successful execution of contractual obligations.
The successful candidate will work cross-functionally with Research, Clinical Development, Regulatory Affairs, Commercial, Legal, Finance, Manufacturing, and Executive Leadership to maximize the value of partnerships while proactively identifying and mitigating risks.
The ideal candidate is a strategic, collaborative leader who excels at building trusted partnerships and navigating complex cross-functional environments and coordinating across internal and external stakeholders. They combine scientific understanding with business acumen, possess exceptional communication and influence skills, and have a demonstrated ability to maximize the value of strategic biotechnology alliances while ensuring operational excellence and long-term partner success. They drive alignment between internal priorities and partner expectations and ensure that Tango has a reputation as a good partner.
Strategic Alliance Leadership
Governance & Collaboration
Contract & Financial Management
Issue Resolution & Risk Management
Performance Monitoring
Executive Communication
#LI-hybrid
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medicines.
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
Offices: 201 Brookline Ave, Suite 901, Boston, Massachusetts 02215, US
Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medicines.
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
Offices: 201 Brookline Ave, Suite 901, Boston, Massachusetts 02215, US
